|
|
|
|
|
28.10.26 - 17:42
|
WOCHENVORSCHAU: Termine bis 11. November 2026 (DPA-AFX)
|
|
|
FRANKFURT (dpa-AFX) - Wirtschafts- und Finanztermine bis Mittwoch, den 11. November^---------------------------------------------------------------------------------------DONNERSTAG, DEN 29. OKTOBERTERMINE UNTERNEHMEN02:00 KOR: Samsung, ......
|
|
|
28.10.26 - 17:42
|
TAGESVORSCHAU: Termine am 29. Oktober 2026 (DPA-AFX)
|
|
|
FRANKFURT (dpa-AFX) - Wirtschafts- und Finanztermine am Donnerstag, den 29. Oktober^TERMINE UNTERNEHMEN02:00 KOR: Samsung, Q3-Zahlen06:00 NOR: Aker ASA, Q3-Zahlen06:30 FRA: Societe Generale, Q3-Zahlen06:30 NLD: Redcare ......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28.10.26 - 08:30
|
Samsung C&T Earnings Decline In Q3 (AFX)
|
|
|
SEOUL (dpa-AFX) - Samsung C&T Corp. (028260.KS, 02826K.KS), a South Korean construction and engineering company, on Wednesday reported a decline in net income despite higher sales in the third qua......
|
|
|
28.10.26 - 08:06
|
Samsung Epis Holdings Reports Third Quarter 2026 Financial Results and Business Update (Business Wire)
|
|
|
Third-quarter revenue reaches KRW 442.2 billion and operating profit KRW 132.6 billion; milestone-excluded product sales increase 4.1% and operating profit rises 21.3% year-over-year (YoY) driven by EPYSQLI® (eculizumab-aagh) in the United States (US) and PYZCHIVA™ (ustekinumab) in Europe
Accelerating pipeline with nine next-generation biosimilars and multiple novel therapeutics, including submission of Marketing Authorization Application for SB27, a proposed biosimilar to Keytruda (pembrolizumab), in Korea, and FDA Fast Track designation for novel antibody-drug conjugate (ADC) candidate SBE303
INCHEON, Korea--(BUSINESS WIRE)--#ADCs--Samsung Epis Holdings (KRX: 0126Z0), a holding company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the third quarter and first nine months of fiscal year 2026.
“Our performance in the first nine months underscores the continued commercial resilience and underlying earnings power of our biosimilar portfolio...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
